

CATALYST PHARMACEUTICAL PARTNERS, INC.

Form 8-K

February 14, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF**

**THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of Earliest Event Reported): February 11, 2013**

**CATALYST PHARMACEUTICAL PARTNERS, INC.**

(Exact Name Of Registrant As Specified In Its Charter)

**Delaware**  
(State or other jurisdiction

of incorporation)

**001-33057**  
(Commission

File Number)

**76-0837053**  
(I.R.S. Employer

Identification No.)

Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 8-K

**355 Alhambra Circle**

**Suite 1500**

**Coral Gables, Florida**

**(Address of principal executive offices)**

**Registrant's telephone number, including area code: (305) 529-2522**

**33134**

**(Zip Code)**

**Not Applicable**

**Former Name or Former address, if changed since last report**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure**

On February 11, 2013, the Company posted on its website the presentation materials from the Company's presentation at the 15<sup>th</sup> Annual BIO CEO & Investor Conference, held at the Waldorf Astoria Hotel in New York City, New York. The presentation is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

The information in Item 7.01 of this Current Report on Form 8-K, including the presentation attached as Exhibit 99.1 hereto, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities under that Section. The information in Item 7.01 of this Current Report shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing or document.

**Item 8.01 Other Events**

On February 11, 2013, the Company issued a press release updating the market on the status of the research and development pipeline for its product candidates Firdapse, CPP-115 and CPP-109. The press release is attached to this Current Report on Form 8-K as Exhibit 99.2 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(c) Exhibits

99.1 Information posted on Company's website on February 11, 2013

99.2 Press Release issued by the Company on February 11, 2013

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Catalyst Pharmaceutical Partners, Inc.**

By: /s/ Alicia Grande  
Alicia Grande  
Vice President, Treasurer and CFO

Dated: February 11, 2013